BTLA[Biotin], His & Avi, Human
BTLA[Biotin], His & Avi, Human

Immobilized BTLA[Biotin], His & Avi, Human, His Tag at 2 μg/ml(100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Human HVEM, hFc Tag with the EC50 of 8.6 ng/ml determined by ELISA.

BTLA[Biotin], His & Avi, Human

Immobilized Anti-BTLA Antibody, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for BTLA[Biotin], His & Avi, Human, His Tag with the EC50 of 7.8 ng/ml determined by ELISA.

BTLA[Biotin], His & Avi, Human

The purity of BTLA[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC

BTLA[Biotin], His & Avi, Human

BTLA[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

BTLA[Biotin], His & Avi, Human

B- and T-lymphocyte attenuator (BTLA; CD272) is a 35 kDa type I transmembrane glycoprotein in the CD28 family of T cell costimulatory molecules. BTLA is a inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. BTLA may interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14.
Z04416
¥123,118.00

Ask us a question
Product Introduction
Species Human
Protein Construction
BTLA (Lys31-Ser150)
Accession # Q7Z6A9-1		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 16.7 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 38-50 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • BTLA[Biotin], His & Avi, Human
    • BTLA[Biotin], His & Avi, Human

    Immobilized BTLA[Biotin], His & Avi, Human, His Tag at 2 μg/ml(100 μl/well) on the streptavidin precoated plate(5 μg/ml). Dose response curve for Human HVEM, hFc Tag with the EC50 of 8.6 ng/ml determined by ELISA.

  • BTLA[Biotin], His & Avi, Human
    • BTLA[Biotin], His & Avi, Human

    Immobilized Anti-BTLA Antibody, hFc Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for BTLA[Biotin], His & Avi, Human, His Tag with the EC50 of 7.8 ng/ml determined by ELISA.

  • BTLA[Biotin], His & Avi, Human
    • BTLA[Biotin], His & Avi, Human

    The purity of BTLA[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC

  • BTLA[Biotin], His & Avi, Human
    • BTLA[Biotin], His & Avi, Human

    BTLA[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background B- and T-lymphocyte attenuator (BTLA; CD272) is a 35 kDa type I transmembrane glycoprotein in the CD28 family of T cell costimulatory molecules. BTLA is a inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. BTLA may interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14.
Synonyms CD272; BTLA; BTLA1; FLJ16065; MGC129743

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.